---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-008521"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2024-03-19T23:59:59+00:00"
generated_at: "2026-06-04T13:09:52.498061+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# DiaMedica FY2023: $52.9M cash, ReMEDy2 interim enrollment Q1 2025, CMO hired

## Summary
- Cash and investments $52.9M at Dec 31, 2023, up from $33.5M; net cash used in ops $18.7M.
- R&D expenses $13.1M (up 68% YoY) due to in-use studies and DM199 manufacturing; G&A $8.2M (up 32%).
- ReMEDy2 Phase 2/3 trial: 6 U.S. sites open; interim enrollment of 144 patients expected by Q1 2025.
- Protocol modified to focus on moderate AIS (NIHSS 5-15) and exclude posterior strokes to boost efficacy.
- Appointed Dr. Lorianne Masuoka as CMO in Jan 2024 and Rebekah de Vitry Fries as VP Clinical Operations.

## SEC filing metadata
- accession: 0001437749-24-008521
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2024-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774924008521/0001437749-24-008521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774924008521/dmtp20240318_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-008521
- JSON: https://secwatch.observer/filing/0001437749-24-008521.json
- Plain text: https://secwatch.observer/filing/0001437749-24-008521.txt

## Key facts
- Earnings Releases
  DiaMedica Therapeutics Inc. reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On March 19, 2024, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1401040/000143774924008521/0001437749-24-008521-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.